Ali-Jackson Kamil sold $73K of RIGL
Ali-Jackson Kamil sold 2,500 shares of RIGEL PHARMACEUTICALS INC (RIGL) at $29.17 on 2026-05-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director sold $72,925 worth of shares via an open-market transaction under a pre-arranged Rule 10b5-1 plan, which typically limits interpretive value for future performance.
Market read
Traders may note the insider sale, but the 10b5-1 structure makes it unlikely to drive a fundamental repricing.
What to watch
The filing does not state any change in business outlook, clinical progress, or financing needs, so traders should avoid extrapolating fundamentals from the sale alone.
Background
The article is an SEC Form 4 insider transaction disclosure for Rigel Pharmaceuticals (RIGL).
Ticker impact
RIGL disclosed an insider open-market sale by director Ali-Jackson Kamil of 2,500 shares at $29.1700 on May 26.
Likely minimal immediate price impact; any effect is more sentiment than fundamentals.
The filing is a scheduled 10b5-1 sale and does not include new operational, regulatory, or financial guidance.
Market effects
No clear sector read-through; this is company-specific insider trading disclosure.
None.
None.
Counterpoint
Insider sales can be purely liquidity-driven even without 10b5-1, but here the plan is explicitly pre-arranged, further reducing interpretive value.
Key entities
- issuerRIGEL PHARMACEUTICALS INC
Company that filed the Form 4 insider transaction disclosure.
- insiderAli-Jackson Kamil
Director who sold 2,500 shares at $29.1700 on 2026-05-26 under a 10b5-1 plan.
